Docon Technologies Updates Encumbrance Disclosure for Thyrocare Technologies Shares Following Partial NCD Redemption

2 min read     Updated on 01 Apr 2026, 10:52 AM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Docon Technologies Private Limited updated its SEBI SAST disclosure following API Holdings Limited's partial redemption of INR 1,200 million Series 1 NCDs on March 30, 2026, through face value reduction from INR 10,00,000 to INR 9,00,000 per debenture. The number of encumbered Thyrocare Technologies shares remains unchanged at 9,69,69,696 shares (60.93% of share capital), with encumbrance continuing in favor of Catalyst Trusteeship Limited as Debenture Trustee.

powered bylight_fuzz_icon
36566531

*this image is generated using AI for illustrative purposes only.

Docon Technologies Private Limited has filed an updated disclosure under Regulation 31 of SEBI (SAST) Regulations, 2011, regarding the encumbrance on shares of Thyrocare Technologies Limited. The update follows a significant corporate action by API Holdings Limited involving the partial redemption of its Series 1 Non-Convertible Debentures.

Partial Redemption Details

API Holdings Limited executed a partial redemption of its Series 1 Non-Convertible Debentures aggregating to INR 1,200 million on March 30, 2026. The redemption was structured through a reduction in face value per debenture from INR 10,00,000 to INR 9,00,000.

Parameter: Details
Redemption Amount: INR 1,200 million
Redemption Date: March 30, 2026
Face Value Reduction: INR 10,00,000 to INR 9,00,000 per debenture
Method: Reduction of face value per debenture

Share Encumbrance Status

Despite the partial redemption, there has been no change in the number of encumbered shares of Thyrocare Technologies Limited held by Docon Technologies Private Limited. The encumbrance details remain as follows:

Metric: Current Position
Encumbered Shares: 9,69,69,696 shares
Percentage of Total Share Capital: 60.93%
Encumbrance Holder: Catalyst Trusteeship Limited
Capacity: Debenture Trustee for NCDs issued by API Holdings Limited

Updated Debenture Structure

Following the partial redemption, the Series 1 Debentures now comprise 12,000 unlisted, unrated, secured, redeemable, non-convertible debentures with a reduced face value of INR 9,00,000 per debenture, aggregating to a nominal value of INR 10,800 million.

Major Debenture Holders

The disclosure reveals the current composition of debenture holders following the redemption:

Debenture Holder: Amount (INR Million)
360 One Prime Limited: 2,497.50
Micro Labs Limited: 2,266.20
Tata Capital Limited: 1,125.00
360 One Commercial Yield Fund: 810.00
360 One Real Assets Advantage Fund: 657.00
J Kumar Infraprojects Limited: 540.00
Bennett Coleman And Company Limited: 450.00

Regulatory Compliance

The updated disclosure was made to both the National Stock Exchange of India Limited and BSE Limited, along with Thyrocare Technologies Limited, in compliance with Regulation 31 of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. This follows previous disclosures made on September 24, 2025, November 11, 2025, and December 05, 2025.

The encumbrance on Docon's shares was created pursuant to a corporate guarantee extended by Docon Technologies Private Limited to secure the obligations of API Holdings Limited, its holding company, in respect of facilities availed through the issuance of the non-convertible debentures.

Historical Stock Returns for Thyrocare Technologies

1 Day5 Days1 Month6 Months1 Year5 Years
+3.56%-3.03%-8.04%-6.43%+50.48%+24.23%

Will API Holdings pursue further partial redemptions of the remaining INR 10,800 million debentures given the successful completion of this INR 1,200 million redemption?

How might the continued encumbrance of 60.93% of Thyrocare's shares impact potential strategic decisions or M&A activities for the company?

What factors could lead to the release of the share encumbrance held by Catalyst Trusteeship Limited in the near term?

like18
dislike

Thyrocare Technologies Receives ₹2.03 Crore Tax Demand Notice from Income Tax Department

1 min read     Updated on 29 Mar 2026, 08:43 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Thyrocare Technologies Limited received a Notice of Demand for ₹2,02,82,260 from the Income Tax Department under Section 156 of the Income-tax Act, 1961 for Assessment Year 2024-25. The notice was dated March 27, 2026 and received on March 28, 2026. The company states there is no material impact on its operations except for the specified amount and considers the demand litigative, planning to contest it before appropriate authorities within prescribed timelines.

powered bylight_fuzz_icon
36342839

*this image is generated using AI for illustrative purposes only.

Thyrocare Technologies Limited has received a tax demand notice from the Income Tax Department, requiring the diagnostic services company to pay ₹2,02,82,260 for Assessment Year 2024-25. The company disclosed this development through a regulatory filing under SEBI's Listing Obligations and Disclosure Requirements Regulations, 2015.

Notice Details and Timeline

The Income Tax Department issued the Notice of Demand under Section 156 of the Income-tax Act, 1961, dated March 27, 2026. Thyrocare Technologies received this notice on March 28, 2026, from the Assessment Unit of the Income Tax Department.

Parameter: Details
Notice Type: Notice of Demand under Section 156
DIN Number: ITBA/AST/S/156/2025-26/1088013634(1)
Notice Date: March 27, 2026
Receipt Date: March 28, 2026
Assessment Year: 2024-25
Demand Amount: ₹2,02,82,260

Financial Impact Assessment

According to the company's disclosure, there is no material impact on the financials, operations, or other activities of Thyrocare Technologies, except for the amount mentioned in the notice. The financial exposure of ₹2,02,82,260 may become payable to the authorities only if the company's submissions are not accepted by the Income Tax Department.

Company's Response Strategy

Thyrocare Technologies has indicated that it considers the demand specified in the notice as litigative in nature. The company plans to contest the demand before the appropriate authorities within the stipulated timelines as provided under the law.

The company's planned actions include:

  • Evaluating the matter thoroughly
  • Submitting an appropriate response to the tax authorities
  • Filing a reply or appeal before the appropriate authority within prescribed timelines
  • Contesting the demand through proper legal channels

Regulatory Compliance

The disclosure was made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has also disseminated this information on its official website at investor.thyrocare.com to ensure transparency with stakeholders.

Brijesh Kumar, Company Secretary and Compliance Officer of Thyrocare Technologies Limited, signed the regulatory filing on March 29, 2026. The company has confirmed that no penalties, restrictions, or sanctions have been imposed as part of this communication, and no aberrations or non-compliances were specifically identified by the authorities in the notice.

Historical Stock Returns for Thyrocare Technologies

1 Day5 Days1 Month6 Months1 Year5 Years
+3.56%-3.03%-8.04%-6.43%+50.48%+24.23%

How might this tax dispute affect Thyrocare's cash flow and working capital management in the coming quarters?

Could this tax demand signal broader scrutiny of the diagnostic services sector by income tax authorities?

What impact might prolonged tax litigation have on Thyrocare's ability to pursue expansion plans or strategic investments?

like15
dislike

More News on Thyrocare Technologies

1 Year Returns:+50.48%